745P - Paclitaxel and cisplatin combined with intensity-modulated radiotherapy for upper esophageal carcinoma

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Anticancer agents
Oesophageal Cancer
Surgical Oncology
Biological Therapy
Radiation Oncology
Presenter Lingli Tu
Authors L. Tu1, L. Sun2, Y. Gong2, Y. Liu2, L. Zhou2, X. Zhou3, Y. Xu2, J. Wang2, M. Hou2, Y. Lu3
  • 1Division Of Thoracic Oncology Dept., West China Hospital, Cancer Center, Sichuan University, 86 - Chengdu/CN
  • 2Department Of Thoracic Oncology, West China Hospital, Cancer Center, Sichuan University, 86 - Chengdu/CN
  • 3Department Of Thoracic Oncology, West China Hospital, Sichuan University, 86 - 610041/CN



Concurrent radio-chemotherapy has been recommended as a standard therapy in patients with upper esophageal carcinoma which is not suitable for surgery. Although INT 0123 trial indicated that the 5-fluorouracil (5-FU) plus cisplatin (DDP) combined with radiotherapy was the initial strategy, the optimal management of upper esophageal carcinoma remains undetermined. This study was conducted to evaluate the effectiveness and safety of intensity-modulated radiotherapy (IMRT) and concurrent paclitaxel plus cisplatin (TP regimen) for upper esophageal carcinoma.

Materials and methods

36 patients of upper esophageal carcinoma were retrospectively analyzed. Patients were treated with IMRT (median 60 Gy) combined with concurrent TP regimen chemotherapy. The Kaplan-Meier analysis was performed in statistical analysis. Toxicities were recorded according to the NCI CTC version 3.0.


36 patients aged 43-73 years (median 57 years). The median follow-up period was 14.0 months. The 1-year and 2-year survival rates were 83.3% and 42.8%, respectively. The median progression-free survival (PFS) time and overall survival (OS) time were 12.0 (95% CI 8.6-15.4 months) and 18.0 months (95% CI 14.2-21.8 months), respectively. Grade 3 neutropenia, radiation-induced esophagitis and radiodermatitis were observed in 5 (13.9%), 3 (8.3%) and 8 (22.2%) patients, respectively. There were two treatment-related deaths due to esophageal perforation and hemorrhea.


For those patients with upper esophageal carcinoma, IMRT combined with concurrent TP regimen chemotherapy was an effective treatment. However, special attention should be paid to the occurrence of perforation and hemorrhea.


All authors have declared no conflicts of interest.